Clinical trials: Meningitis, Bacterial
Infections, Papillomavirus
Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a…
- Trial name
- NCT00369824
- Testing
- Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM
- Where
- 50 sites in United States
- Volunteers
- 1,330 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningitis, Cryptococcal, HIV Infections
A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.
To evaluate and estimate the safety and efficacy of the combination of fluconazole and flucytosine as treatment for acute cryptococcal meningitis in patients with AIDS.
- Trial name
- NCT00002113
- Testing
- Flucytosine, Fluconazole
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Pfizer
Cryptococcal Meningitis
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)
This study is designed as two sequential trials. The first is a phase I open label trial to evaluate the safety and tolerability of MAT2203.
- Trial name
- EnACT (NCT04031833)
- Testing
- MAT2203, Amphotericin B
- Where
- Uganda
- Volunteers
- 178 people
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Meningitis, Meningococcal Infection
Dose Comparison Study of Menactra® in US Children
To explore the potential benefit of the administration of Menactra vaccine as a two-dose regimen to children. Primary Objective: To assess, by age group, the immune response to Menactra vaccine after each vaccine injection.
- Conditions
- Meningitis, Meningococcal Infection, Neisseria Meningitidis
- Trial name
- NCT00700635
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
- Where
- 15 sites in United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningitis, Cryptococcal, HIV Infections
Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
To evaluate the safety and effectiveness of fluconazole as treatment for acute cryptococcal meningitis in AIDS patients. Both newly diagnosed and relapsed patients are eligible.
- Trial name
- NCT00002076
- Testing
- Fluconazole
- Where
- 3 sites in United States
- Sponsor
- Pfizer
Meningitis, Meningococcemia
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
This study was designed to simulate meningococcal challenge by vaccination with a fractional combined dose of unconjugated meningococcal polysaccharides A, C, Y, and W-135, Menomune® in children who were vaccinated with one dose…
- Conditions
- Meningitis, Meningococcemia, Neisseria Meningitidis
- Trial name
- NCT00772070
- Testing
- A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
- Where
- 8 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningitis, Meningococcal
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months
The purpose of this study is to evaluate the immunogenicity and safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 to 5 months.
- Trial name
- NCT05252715
- Testing
- Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, Meningococcal A and C Polysaccharide Conjugate Vaccine
- Where
- 2 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Meningitis, Meningococcal
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age
MenACWY (Menveo) is a GSK vaccine intended for protection against disease caused by meningococcal bacteria groups A, C, W and Y in infants, children and adults, licensed in more than 60 countries.
- Trial name
- NCT03433482
- Testing
- MenACWY liquid, MenACWY
- Where
- 49 sites in Brazil, Estonia and 7 more
- Volunteers
- 1,707 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease
Safety Surveillance of MenACWY-CRM Vaccine in Children
The purpose of this study is to summarize the occurrence of incident serious medically attended events and events of interest up to 1 year following MenACWY-CRM vaccination administered as part of routine clinical care.
- Trial name
- NCT01452438
- Testing
- MenACWY-CRM
- Where
- United States
- Volunteers
- 393 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Candidiasis, Systemic, Candida Meningitis
Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis
The primary purpose of this study is to evaluate the pharmacokinetic profile of micafungin administered to neonates suffering from systemic candidiasis.
- Trial name
- NCT03421002
- Testing
- Micafungin
- Where
- 2 sites in Italy
- Volunteers
- 35 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Meningitis, Cryptococcal, HIV Infections
A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis
To compare the safety and effectiveness of fluconazole and amphotericin B, alone or in combination with flucytosine, as treatment for acute cryptococcal meningitis.
- Trial name
- NCT00002305
- Testing
- Flucytosine, Fluconazole, Amphotericin B
- Where
- 45 sites in United States, Canada
- Sponsor
- Pfizer
Meningococcal Disease
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
The primary purpose of this study is to evaluate the persistence of bactericidal antibodies in children of approximately 22 to 45 months of age previously enrolled in the V59P22 study (NCT00667602) who received Novartis MenACWY…
- Trial name
- NCT01345721
- Testing
- MenACWY-CRM
- Where
- 11 sites in Germany
- Volunteers
- 205 people
- Sponsor
- Novartis Vaccines
Meningococcal Disease, Meningococcal Meningitis
Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines
This study will evaluate safety, tolerability, and immunogenicity of a booster dose of a meningococcal vaccine formulation in adolescents.
- Trial name
- NCT01367158
- Testing
- Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Tdap
- Where
- 7 sites in Chile, Colombia and 1 more
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningitis, Cryptococcal, HIV Infections
Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
To evaluate the safety and effectiveness of fluconazole as an intravenous dose as initial treatment for acute cryptococcal meningitis followed by oral therapy in AIDS and non-AIDS patients.
- Trial name
- NCT00002040
- Testing
- Fluconazole
- Where
- 5 sites in United States
- Sponsor
- Pfizer
Meningococcal Meningitis, Meningococcal Infections
Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants
This study is aimed at assessing the safety and immunogenicity of different doses and formulations of a new Novartis Meningococcal B Recombinant Vaccine.
- Trial name
- NCT00937521
- Testing
- Meningococcal B vaccine, Control, Meningococcal B vaccine with antipyretic
- Where
- 38 sites in Argentina, Chile and 3 more
- Volunteers
- 1,507 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Meningitis
Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)
This observer-blind, randomized, active controlled trial will be conducted among 2-29 year olds in two sites (Mali and The Gambia).
- Trial name
- NCT03964012
- Testing
- NmCV-5, Menactra
- Where
- 2 sites in Mali, The Gambia
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Meningococcal Meningitis
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds
This is a randomized, blinded, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1 ratio.
- Trial name
- NCT06700148
- Testing
- MCV4, MPSV4
- Where
- 2 sites in China
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Meningitis, Meningococcal Meningitis
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
The purpose of this trial is to describe antibody persistence and response to re-vaccination with either Menactra® or Menomune® vaccine approximately three years following initial vaccination in adults who participated in trial…
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections
- Trial name
- NCT01239043
- Testing
- Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide, Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 6 sites in United States
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Sanofi
Bacterial Meningitis
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India
This study will evaluate the immunogenicity of a single injection of Novartis Meningococcal ACWY conjugate vaccine in healthy subjects from the age of 2 years and above in India.
- Trial name
- NCT01547715
- Testing
- Meningococcal ACWY conjugate vaccine
- Where
- 4 sites in India
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Novartis
Meningitis, Meningococcal Meningitis
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers
The purpose of the study was to evaluate the immunogenicity and safety profile of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid (MenACYW) Conjugate vaccine when given alone compared to…
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections
- Trial name
- NCT03205358
- Testing
- Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine
- Where
- 8 sites in Finland
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company